CAMBRIDGE, Mass. — Sensorion, a clinical-stage biotechnology company developing treatments for hearing loss, announced the appointment of Peter Weber, MD, MBA, as chief medical officer, effective November 2, 2026.
Weber, an otologist and neurotologist with more than 20 years of clinical and industry experience, joins Sensorion as the company prepares to advance SENS-601, a gene therapy targeting a common genetic cause of hearing loss, into clinical development.
Weber previously served as chief medical officer of Decibel Therapeutics and later as senior medical consultant to Regeneron, where he helped guide several gene therapy programs for inherited hearing disorders. His work included the development of an otoferlin gene therapy that became the first FDA-approved gene therapy for genetic hearing loss.
At Decibel, he also oversaw a small-molecule development program aimed at preventing hearing loss associated with cisplatin chemotherapy.
Most recently, Weber served as chief medical officer of Auregen BioTherapeutics, where he led a Phase I/II clinical trial evaluating an autologous, 3D-printed cartilage implant for children with microtia, a congenital ear condition. He also directed regulatory efforts that secured Orphan Drug and Breakthrough designations.
His previous leadership positions include chief medical officer of Frequency Therapeutics, where he oversaw early clinical development of a treatment designed to regenerate cochlear hair cells, and global chief medical officer at Cochlear Limited, where he managed regulatory submissions for medical devices.
Weber is also a professor and head of Otology, Neurotology and Skull Base Surgery at Boston University Medical Center. He previously held academic positions at Mount Sinai Health System, the University of Massachusetts Medical Center, Cleveland Clinic and the Medical University of South Carolina.
He has served as editor-in-chief of the American Journal of Otolaryngology since 2002 and has authored more than 125 scientific publications and three books.
“Having worked on some of the first gene therapies for genetic forms of hearing loss, including otoferlin-related hearing loss, I have seen what these treatments can mean for children and their families,” Weber said. “I have also seen how quickly the field has matured. SENS-601 targets one of the most common genetic causes of hearing loss, so it has the potential to reach a much larger patient population.”
Frédéric Chereau, chief executive officer of Sensorion, said Weber’s experience in clinical development and regulatory approvals would support the company’s expanding gene therapy pipeline.
“Peter combines decades of hands-on clinical practice in otology and neurotology with direct experience leading gene therapy programs for hearing loss, including otoferlin-related hearing loss,” Chereau said. “Few people have taken inner-ear gene therapy from the clinic toward approval.”
Weber holds a medical degree from Albany Medical College, an MBA from Duke University and undergraduate and graduate degrees in chemical and biomedical engineering from Washington University in St. Louis.
